+AA
Fr
Back
Clinician Article

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.



  • Singh JA
  • Saag KG
  • Bridges SL Jr
  • Akl EA
  • Bannuru RR
  • Sullivan MC, et al.
Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6. (Review)
PMID: 26545940
Read abstract Read evidence summary Read full text
Disciplines
  • Rheumatology
    Relevance - 7/7
    Newsworthiness - 5/7
  • Internal Medicine
    Relevance - 6/7
    Newsworthiness - 7/7
  • Family Medicine (FM)/General Practice (GP)
    Relevance - 6/7
    Newsworthiness - 6/7
  • General Internal Medicine-Primary Care(US)
    Relevance - 6/7
    Newsworthiness - 6/7

Abstract

OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA).

METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.

RESULTS: The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.

CONCLUSION: This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.


Clinical Comments

Family Medicine (FM)/General Practice (GP)

Very useful overview of current best practice. As a family doctor, it would help me to guide patients appropriately. With a bit of help, many patients would find this useful.

General Internal Medicine-Primary Care(US)

The article summarizes the American College of Rheumatology's recommendations for treating rheumatoid arthritis. Given the rapid changes in the treatment of this condition, I believe most general internists would refer their patients with rheumatoid arthritis to a rheumatologist to have evaluations at regular intervals. The section on immunization recommendations might be helpful for managing RA patients who do not see a rheumatologist regularly.

Internal Medicine

More useful for rheumatologists than internists.

Internal Medicine

Excellent guideline statement for anyone treating patients with RA.

Register for free access to all Professional content

Register
Want the latest in aging research? Sign up for our email alerts.
Subscribe
© 2012 - 2019 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | +1 905-525-9140 | Terms Of Use